Llwytho...
Randomized Phase II Trial of Bevacizumab plus Everolimus versus Bevacizumab Alone for Recurrent or Persistent Ovarian, Fallopian Tube or Peritoneal Carcinoma: an NRG Oncology/Gynecologic Oncology Group Study
PURPOSE: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathways, resulting in mTOR activation. We evaluated combining BV and everolimus (EV), an mTOR kinase inhibitor, to circumvent BV-resistance in women with recurrent or persistent ovarian, fallopian tube or...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Gynecol Oncol |
|---|---|
| Prif Awduron: | , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6350932/ https://ncbi.nlm.nih.gov/pubmed/30177462 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.08.027 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|